Entero Healthcare Clarifies Q4 FY26 Profit & Minority Interest

Key Quantitative Figures

• One-off items impacting profit: INR 114 million
• Ownership stake acquired in Anand Chemiceutics Private Limited: 51.51%

Details of Clarification

1. Profit Attributable to Owners of the Company

The Company reported operational growth during the quarter, but profit growth was impacted by specific one-off items totaling INR 114 million. These items comprised:

• Costs associated with closure of a business contract
• Higher provisioning charges and write-offs

These items originated from Entero's Standalone Financials and its Wholly Owned Subsidiaries, directly affecting the profit attributable to the owners of the Company.

2. Increase in Non-Controlling Interest (Minority Interest)

The increase in non-controlling interest during the quarter is primarily attributable to the acquisition of Anand Chemiceutics Private Limited, which was completed during the Quarter. The Company acquired a 51.51% ownership stake in this subsidiary.

As a result of this acquisition, a higher share of profits attributable to minority shareholders of this subsidiary has been reflected under non-controlling interest in the Consolidated Financial Statements.

Purpose and Rationale

The clarification was submitted to ensure transparency and adequate dissemination of information to investors regarding the Q4 FY26 financial results.